Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MPL-001

Phase 2Small molecule

UUniversity of Manitoba

1

Indications

3

Total Trials

2

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Pediatric

NCT05754840

Clinical

Trials by Indication[1]

Pediatric1 trial

CANnabinoids in Pediatric ONCology

Not yet recruiting·UUniversity of Manitoba·Phase 1/2·NCT05754840·60 enrolled

Post-surgical Pain1 trial

Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT

Completed·MMcMaster University·Phase 3·NCT03825965·39 enrolled

Headache1 trial

Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

Recruiting·UUniversity of Manitoba·Phase 2·NCT05337033·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MPL-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MPL-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MPL-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Manitoba company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Manitoba

Related News